RESUMEN
Objective To investigate the early prediction and monitoring value of real time fluorescence quantitative PCR(qPCR) detection of BCR-ABL mRNA on chronic myelogenous leukemia(CML)patients with minimal residual disease(MRD)after alloge-neic hematopoietic stem cell transplantation(allo-HSCT).Methods From January 2013 to January 2016 in People's Hospital of Yantian District,School of Medicine in Shenzhen University and Shenzhen Hospital of Peking University,67 cases of outpatient and hospitalized patients with chronic myelogenous leukemia in the Department of Hematology were selected as the observation group, and 50 healthy people who took physical examination in the People's Hospital of Yantian District at the same period of time were se-lected as the control group.BCR-ABL mRNA levels before and after allogeneic hematopoietic stem cell transplantation in patients with chronic myelocytic leukemia were detected by qPCR.Results The BCR-ABL mRNA results in the control group were nega-tive.Before transplantationin the levels of BCR-ABL mRNA in patients with CML in accelerated and blastic phase were higher than that in patients in chronic phase(P<0.05);After transplantation the BCR-ABL/ABL ratio of qPCR detected at all time points in the first 36 months was significantly lower than that before the transplantation,and the difference was statistically significant(P<0.05);qPCR can still detect the level of BCR-ABL/ABL expression after 36 months of transplantation.Conclusion qPCR is accu-rate and reliable,and has important clinical application value for the clinical diagnosis of chronic myeloid leukemia and minimal re-sidual disease detection.
RESUMEN
Objective To evaluate significance of the quantification of bcr-abl mRNA in diagnosis and therapy of chronic myeloid leukemia (CML),essentiality significance for monitoring minimal residual disease. Methods Bcr-abl mRNA of 518 CML patients were detected using real-time PCR. Results Expression of bcr-abl mRNA was gradually increased among blastic phase (BP) (12.6 %),accelerated phase (AP) (25.4 %) and chronic phase (CP) (57.2 %) (P<0.05). Quantification of bcr-abl mRNA was cut down gradually after allotransplantation in the patients and becomes normal after treatment for 6 months. But quantification of bcr-abl mRNA inpatients treated with imatinib mesylate became normal after 12 months. Conclusion Real-time PCR was reliable and can be used for diagnosis,monitoring the treatment outcome,detecting the minimal residual disease,and predicting blast crisis.
RESUMEN
Biphenotypic acute leukemia (BAL) is a subtype of leukemia of ambiguous lineage in the World Health Organization classification system. About one third of the cases have the Philadelphia chromosome, and some cases are associated with other structural abnormalities involving 11q23. BAL is known to have a poor prognosis in both children and adults. According to the previously reported BAL cases with positive BCR-ABL fusion gene, most of the BCR-ABL mRNA transcript type was e1a2. So, we describe here a 30-year-old adult BAL case with the karyotype 46,XY,t(9;22)(q34;q11.2) resulting in a very rare b3a2 type of BCR-ABL mRNA transcript.